Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-10-30 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 7291R' and contains the standard formatting for a regulatory notification disseminated via RNS (Regulatory News Service). The content details a 'TR-1: Standard form for notification of major holdings' concerning an acquisition or disposal of voting rights by UBS Group AG. This type of filing, which reports changes in significant share ownership crossing specific thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-10-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 7259R" and contains the standard formatting and boilerplate language associated with Regulatory News Service (RNS) announcements from the London Stock Exchange. The content details a 'TR-1: Standard form for notification of major holdings' by Societe Generale, indicating a change in voting rights crossing a threshold. This type of mandatory disclosure regarding significant share ownership changes falls under the category of Major Shareholding Notification (MRQ). Although RNS is the distribution mechanism, MRQ is the specific regulatory filing type being reported.
2023-10-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 7193R" and contains the standard header/footer information associated with RNS (Regulatory News Service) announcements from the London Stock Exchange. The content details a 'TR-1: Standard form for notification of major holdings' by Barclays PLC regarding an acquisition/disposal of voting rights, which is a specific type of regulatory disclosure concerning significant share ownership changes. This fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is moderate (5042 chars), but the content is a standardized notification form, not a comprehensive report itself.
2023-10-30 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used in the context of a takeover or merger activity to disclose holdings and transactions by parties involved. This directly aligns with the definition of M&A Activity (TAR), which covers merger proposals or takeover bids, as this disclosure is a mandatory filing during such an event. It is not a general regulatory filing (RNS) because it is highly specific to takeover rules, nor is it a Director's Dealing (DIRS) as the discloser is Millennium International Management LP, an investment manager, not necessarily a director of Dechra Pharmaceuticals plc.
2023-10-27 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates directly to an ongoing takeover or merger activity involving the target company (Dechra Pharmaceuticals plc) and is a mandatory filing under UK takeover rules. Among the provided categories, 'M&A Activity (Code: TAR)' is the most appropriate classification for documents detailing dealings or positions related to a takeover bid governed by the Takeover Code.
2023-10-26 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 4458R' and contains the standard boilerplate text indicating it is provided by RNS, the news service of the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in share ownership by an entity (UBS Group AG) crossing a reporting threshold. This type of filing, reporting changes in significant shareholdings, maps directly to the Major Shareholding Notification category.
2023-10-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.